Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].

Introduction: Standard-dose eribulin mesylate (1.4 mg/m d1 + 8) achieves clinical benefit rates of 26%-52% in patients with metastatic breast cancer (mBC). <10% of patients in the registration trial were ≥ 70 years old; dose reductions were common in these older patients.

[From Gleason score to Ann Arbor staging- a selective choice of important scores and staging systems in oncology].

Hundreds scores and dozens staging systems exist in Oncology. They provide for example information on the spread and prognosis of a disease or are included in treatment decisions. Because of the existing diversity a description of all oncological codes would exceed the scope of this paper, the following articles focuses in the first part on some exemplary and lesser-known scores and in the second part on main staging systems in Oncology.

Nontyphoidal salmonellosis and mycotic aneurysm: a case report.

A 74-year-old male with atherosclerosis presented with severe nontyphoidal salmonellosis, and received outpatient therapeutic antimicrobial treatment. Nevertheless, within seven days he developed a mycotic aortic aneurysm, a serious but treatable complication. Its surgical management was successful.